246 related articles for article (PubMed ID: 12899584)
1. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Devereux RB; Dahlöf B; Kjeldsen SE; Julius S; Aurup P; Beevers G; Edelman JM; de Faire U; Fyhrquist F; Helle Berg S; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
Ann Intern Med; 2003 Aug; 139(3):169-77. PubMed ID: 12899584
[TBL] [Abstract][Full Text] [Related]
2. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristiansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H;
Lancet; 2002 Mar; 359(9311):995-1003. PubMed ID: 11937178
[TBL] [Abstract][Full Text] [Related]
4. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lindholm LH; Ibsen H; Dahlöf B; Devereux RB; Beevers G; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Kristiansson K; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wedel H; Aurup P; Edelman J; Snapinn S;
Lancet; 2002 Mar; 359(9311):1004-10. PubMed ID: 11937179
[TBL] [Abstract][Full Text] [Related]
9. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Kizer JR; Dahlöf B; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Wachtell K; Edelman JM; Snapinn SM; Harris KE; Devereux RB
Hypertension; 2005 Jan; 45(1):46-52. PubMed ID: 15583076
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Franklin SS; Wachtell K; Papademetriou V; Olsen MH; Devereux RB; Fyhrquist F; Ibsen H; Kjeldsen SE; Dahlöf B
Hypertension; 2005 Sep; 46(3):492-9. PubMed ID: 16116047
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
[TBL] [Abstract][Full Text] [Related]
12. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Narayan P; Nieminen MS; Omvik P; Oparil S; Wedel H
Am Heart J; 2009 Jan; 157(1):177-84. PubMed ID: 19081416
[TBL] [Abstract][Full Text] [Related]
14. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
15. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Fyhrquist F; Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Hille DA; Lyle PA; Edelman JM; Snapinn SM; Wedel H;
Hypertension; 2005 Apr; 45(4):580-5. PubMed ID: 15790960
[TBL] [Abstract][Full Text] [Related]
16. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
17. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Ruwald AC; Westergaard B; Sehestedt T; Kjeldsen SE; Lindholm LH; Wachtell K; Devereux RB; Ibsen H; Nieminen MS; Dahlöf B; Olsen MH
J Hypertens; 2012 Jun; 30(6):1252-9. PubMed ID: 22499288
[TBL] [Abstract][Full Text] [Related]
18. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
19. Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Ann Intern Med; 2003 Aug; 139(3):I28. PubMed ID: 12899605
[No Abstract] [Full Text] [Related]
20. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
